Financials in USD. Standardized financial statements.
A compact view of how Aktis Oncology, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue? | $6.50M | $1.49M | $0 | $0 |
| Revenue Growth? | +336.9% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 |
| Gross Profit? | $6.50M | $1.49M | $0 | $0 |
| Gross Margin? | +100.0% | +100.0% | 0.0% | 0.0% |
| Operating Expenses? | $81.18M | $53.54M | $34.79M | $19.76M |
| Operating Income? | -$74.68M | -$52.05M | -$34.79M | -$19.76M |
| EBITDA? | -$72.36M | -$50.48M | -$33.60M | -$19.32M |
| Income Before Tax | -$63.73M | -$43.98M | -$28.64M | -$17.93M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income? | -$63.73M | -$43.98M | -$28.64M | -$17.93M |
| EPS? | $-1.19 | $-1.26 | $-0.82 | $-0.51 |
| Diluted EPS? | $-1.19 | $-1.26 | $-0.82 | $-0.51 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality